Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD2-specific 4SCAR-T cells
- Development stage
- Phase 1
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous, Intracavitary
01
Overview
GD2-specific 4SCAR-T cells are a fourth-generation safety-designed chimeric antigen receptor T cell therapy that targets the GD2 antigen. These engineered T cells incorporate multiple intracellular signaling domains including CD28/4-1BB/CD3ζ-iCasp9 for enhanced activation and safety. The therapy includes an inducible caspase-9 (iCasp9) safety switch that allows for controlled elimination of the CAR-T cells if needed. The cells are genetically modified using lentiviral vectors and are designed to treat GD2-positive tumors including glioblastoma and neuroblastoma. The fourth-generation design aims to improve persistence and reduce toxicity compared to earlier CAR-T cell generations.
- Other names
- GD2-specific fourth-generation safety-designed chimeric antigen receptor T cellsGD-2-specific fourth-generation safety-designed chimeric antigen receptor T cellsGD 2-specific fourth-generation safety-designed chimeric antigen receptor T cells4SCAR-GD2 T cells
02
Targets
GD2
Beyond the preview
Go deeper on GD2-specific 4SCAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GD2-specific 4SCAR-T cells.